ライフサイエンスコーパス: antiphospholipid antibody

1 cardiac foramen ovale, or elevated levels of antiphospholipid antibody.

2 ctive protein (CRP), and the presence of any antiphospholipid antibody.

3 hrombotic risk in asymptomatic patients with antiphospholipid antibodies.

4 recurrent pregnancy failure associated with antiphospholipid antibodies.

5 al anticoagulant and fibrinolytic systems by antiphospholipid antibodies.

6 tion on noncellular phospholipid surfaces by antiphospholipid antibodies.

7 the reduction of surface-bound annexin V by antiphospholipid antibodies.

8 of lupus pregnancy, especially in women with antiphospholipid antibodies.

9 factor VII mutation, factor II mutation, and antiphospholipid antibodies.

10 ished by the 13th International Committee on Antiphospholipid Antibodies.

11 or at risk of, thrombosis in the setting of antiphospholipid antibodies.

12 cular complications of lupus associated with antiphospholipid antibodies.

13 ffective for nonthrombotic manifestations of antiphospholipid antibodies.

14 coprotein I (beta2GPI), the main antigen for antiphospholipid antibodies.

15 ity in the presence of persistently positive antiphospholipid antibodies.

16 disease activity, emotional disturbance, and antiphospholipid antibodies.

17 w that ApoER2 is involved in pathogenesis of antiphospholipids antibodies.

18 The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA)

19 To test this idea, we studied how antiphospholipid antibodies affect levels of annexin V o

20 Antiphospholipid antibodies and CRP support the role of

21 mbocytopenia associated with the presence of antiphospholipid antibodies and persistently positive an

22 lar endothelial cell dysfunction mediated by antiphospholipid antibodies and subsequent complement sy

23 mbotic status of APS patients induced by IgG-antiphospholipid antibodies and the beneficial effects o

24 ress with regard to the relationship between antiphospholipid antibody and its target, beta-2-glycopr

25 n I (beta2GPI; the major autoantigen for the antiphospholipid antibodies) and the homologous catalyti

26 c lupus erythematosus (SLE), 2 patients with antiphospholipid antibodies, and 3 other patients, but a

27 re corticosteroid treatment, the presence of antiphospholipid antibodies, and acute thrombocytopenia.

28 limitations of existing laboratory tests for antiphospholipid antibodies, and the absence of evidence

29 levant risk factors including renal disease, antiphospholipid antibody, and anti-Ro/SS-A and anti-La/

30 Antinuclear, antiphospholipid antibodies, anti-Ro, and anti-La antibo

31 erosclerosis have an increased prevalence of antiphospholipid antibodies (aPL) and antibodies to oxid

32 Although antiphospholipid antibodies (aPL) are associated with ar

33 Pathogenic antiphospholipid antibodies (aPL) bind the self antigen

34 In antiphospholipid syndrome (APS), antiphospholipid antibodies (aPL) binding to beta2 glyco

35 The presence of antiphospholipid antibodies (aPL) has been associated wi

36 Antiphospholipid antibodies (aPL) have been shown to ind

37 Antiphospholipid antibodies (aPL) have thrombogenic prop

38 To test the hypothesis that some antiphospholipid antibodies (aPL) in patients with the a

39 The mechanism leading to the formation of antiphospholipid antibodies (aPL) is still unknown.

40 phospholipid syndrome (APS), suggesting that antiphospholipid antibodies (aPL) may bind platelets, ca

41 Serum antiphospholipid antibodies (aPL) were identified by ant

42 ients had APS, 24 patients were positive for antiphospholipid antibodies (aPL), and 19 patients had S

43 ion with these mutations and the presence of antiphospholipid antibodies (aPL), lupus anticoagulant (

44 a condition characterized by the presence of antiphospholipid antibodies (aPL), often suffer pregnanc

45 d laboratory confirmation of the presence of antiphospholipid antibodies (aPL).

46 poorly known, particularly in the absence of antiphospholipid antibodies (APL).

47 hat has been associated with the presence of antiphospholipid antibodies (aPL).

48 to PON1 activity, SLE risk, lupus nephritis, antiphospholipid antibody (aPL) positivity, and carotid

49 action of WIG in an in vivo murine model of antiphospholipid antibody (aPL)-induced thrombosis and e

50 sis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (th

51 y was to evaluate the safety of rituximab in antiphospholipid antibody (aPL)-positive patients with n

52 physicians in the management of persistently antiphospholipid antibody (aPL)-positive patients.

53 Laboratory evidence of antiphospholipid antibodies (APLA) in patients with a fi

54 Although not all patients with elevated antiphospholipid antibody (aPLA) levels develop complica

55 Patients with antiphospholipid antibodies (APLAs) are at increased ris

56 is and recurrent fetal loss in patients with antiphospholipid antibodies (APLAs).

57 recurrent pregnancy loss in the presence of antiphospholipid antibodies (APLAs).

58 Fetal loss induced by antiphospholipid antibodies (aPLs) in mice is a compleme

59 There are few data on the relationship of antiphospholipid antibodies (aPLs) to pathologically pro

60 Antiphospholipid antibodies are associated with arterial

61 Patients who have circulating antiphospholipid antibodies are at risk for major abdomi

62 Antiphospholipid antibodies are commonly found in patien

63 d detected in clinical laboratory assays for antiphospholipid antibodies are directed against prothro

64 (n = 513; LMWH + LDA) and women negative for antiphospholipid antibodies as controls (n = 791; no tre

65 utcome in women with a history of refractory antiphospholipid antibody-associated pregnancy loss(es)

66 n with aspirin is justified in patients with antiphospholipid antibodies but without a prior history

67 Antiphospholipid antibodies can be detected in roughly 5

68 The field of antiphospholipid antibodies continues to evolve, with ma

69 a component and suggest that the epitopes of antiphospholipid antibodies could include CL or oxidized

70 bset of periodontitis patients with elevated antiphospholipid antibodies could represent a subgroup a

71 Anticoagulation, prednisone dose, and antiphospholipid antibodies did not significantly impact

72 y of stroke, migraine with aura, circulating antiphospholipid antibodies, discontinuation of antiplat

73 Antiphospholipid antibodies disrupt AnxA5 binding, there

74 the mechanism of thrombosis associated with antiphospholipid antibodies found in the rheumatic disea

75 The antiphospholipid antibodies found in this syndrome are d

76 ment, but also regarding the pathogenesis of antiphospholipid antibodies, has emerged.

77 gs of yellow scleral plaques and circulating antiphospholipid antibodies have been proposed as marker

78 rophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG as compared with control I

79 rophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG had faster mean (+/- SE) p

80 onucleoprotein antibodies in 26 percent, and antiphospholipid antibodies in 18 percent.

81 The role of antiphospholipid antibodies in ocular disease has receiv

82 PS) is defined by the persistent presence of antiphospholipid antibodies in patients with a history o

83 een conducted to determine the prevalence of antiphospholipid antibodies in patients with retinal vas

84 Antiphospholipid antibodies in SLE are associated with m

85 The role of antiphospholipid antibodies in the pathogenesis of SLE m

86 Antiphospholipid antibodies including anticardiolipin an

87 thrombosis, fetal loss, and the presence of antiphospholipid antibodies, including anti-beta2-glycop

88 Antiphospholipid antibodies, including anticardiolipin a

89 patients with key clinical manifestations of antiphospholipid antibodies, including patients with ant

90 ion discusses novel pathogenic mechanisms of antiphospholipid antibodies, including the activation of

91 ll lines, wherein HCQ reduced the binding of antiphospholipid antibodies, increased cell-surface AnxA

92 Delineation of the epitopes recognized by antiphospholipid antibodies induced by HIV-1 offers insi

93 These studies show that antiphospholipid antibodies interfere with the binding o

94 of thrombosis and gestational morbidity with antiphospholipid antibodies is termed antiphospholipid s

95 n of disease, hypertension, body mass index, antiphospholipid antibodies, kidney disease, acute throm

96 (P = 0.04) and were also more likely to have antiphospholipid antibodies (lupus anticoagulant) (P = 0

97 e setting of persistently positive levels of antiphospholipid antibodies measured on 2 different occa

98 The induction of ET-1 by antiphospholipid antibodies might contribute to increase

99 Therefore, we asked whether antiphospholipid antibodies might directly reduce annexi

100 The molecular pathways through which antiphospholipid antibodies modulate the mTORC pathway w

101 HCQ reversed the effect of antiphospholipid antibodies on AnxA5 and restored AnxA5

102 otein I (beta(2)-GPI) is a major antigen for antiphospholipid antibodies present in patients with the

103 Antiphospholipid antibody profiles and clinical outcome

104 Antiphospholipid antibodies reduce the levels of annexin

105 Also, exposure to plasmas containing antiphospholipid antibodies reduces annexin-V binding to

106 r assessment in the management of refractory antiphospholipid antibody-related pregnancy loss(es), al

107 Antiphospholipid antibodies remain one of the more commo

108 antibody-positive patients, although lacking antiphospholipid antibodies, shared an amino acid epitop

109 Antiphospholipid antibodies should be sought in all pati

110 r V Leiden, prothrombin 20210A mutation, and antiphospholipid antibodies significantly increases a pa

111 the first direct evidence that a particular antiphospholipid antibody specificity may contribute to

112 Antiphospholipid antibody syndrome (APAS) is characteriz

113 End-stage renal disease (ESRD) patients with antiphospholipid antibody syndrome (APAS) remain at high

114 Antiphospholipid antibody syndrome (APS) is a complex au

115 optimal clinical management of patients with antiphospholipid antibody syndrome (APS) is uncertain be

116 Patients with the antiphospholipid antibody syndrome (APS) often experienc

117 cardiolipin (CL), are found in patients with antiphospholipid antibody syndrome (APS).

118 es that were all isolated from patients with antiphospholipid antibody syndrome (APS); testing was al

119 New antibody tests for antiphospholipid antibody syndrome are available with in

120 wledge of the clinical syndrome that we call antiphospholipid antibody syndrome has also progressed.

121 understanding of the pathophysiology behind antiphospholipid antibody syndrome has led to novel appr

122 idelines for the treatment and management of antiphospholipid antibody syndrome have been established

123 The diagnostic criteria of antiphospholipid antibody syndrome have been reviewed an

124 The antiphospholipid antibody syndrome is an important cause

125 Antiphospholipid antibody syndrome with valvular vegetat

126 rment within SLE and related conditions (eg, antiphospholipid antibody syndrome, active vs inactive S

127 iolipin (anti-CL) antibodies, diagnostic for antiphospholipid antibody syndrome, are associated with

128 d cause valvular vegetations associated with antiphospholipid antibody syndrome, which would be a new

129 id-binding protein and an autoantigen in the antiphospholipid antibody syndrome.

130 ociated with thrombosis in patients with the antiphospholipid antibody syndrome.

131 ave also updated information about pediatric antiphospholipid antibody syndrome.

132 pholipid antibodies, including patients with antiphospholipid antibody syndrome.

133 e appropriate laboratory results make up the antiphospholipid antibody syndrome.

134 d IgG fractions from three patients with the antiphospholipid-antibody syndrome and from normal contr

135 ascular thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome are unknown.

136 nism of thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome.

137 Routine laboratory, autoantibody, and antiphospholipid antibody testing was performed in the h

138 reincubation of healthy monocytes before IgG-antiphospholipid antibody treatment decreased oxidative

139 the molecular and intracellular events that antiphospholipid antibodies trigger in target cells, as

140 actions and the intracellular signaling that antiphospholipid antibodies trigger, new therapeutic and

141 rrent pregnancy loss includes measurement of antiphospholipid antibodies under the perception that th

142 Antiphospholipid antibody was present in a titer of 1:10

143 Rates of antiphospholipid antibodies were low, comparable to thos

144 No antiphospholipid antibodies were present in the patient'

145 Antiphospholipid antibodies were present(defined as IgG

146 olytic anemia, anti-double-stranded DNA, and antiphospholipid antibody were associated with thrombocy

147 pus erythematosus occurs in association with antiphospholipid antibodies, which also are associated w

148 or V antibody not related to the presence of antiphospholipid antibodies, which is responsible for th

149 Eighteen women with antiphospholipid antibodies who had refractory pregnancy

150 ion on biopsy as compared with patients with antiphospholipid antibodies who were not receiving sirol

151 patients, and 0 of 5 cycles in 2 women with antiphospholipid antibody (without SLE or primary APS) r